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Abstract
Background: Mitochondria are a vital component of eukaryotic cells and their dysfunction is implicated in a large
number of metabolic, degenerative and age-related human diseases. The mechanism or these disorders can be
difficult to elucidate due to the inherent complexity of mitochondrial metabolism. To understand how
mitochondrial metabolic dysfunction contributes to these diseases, a metabolic model of a human heart
mitochondrion was created.
Results: A new model of mitochondrial metabolism was built on the principle of metabolite availability using
MitoMiner, a mitochondrial proteomics database, to evaluate the subcellular localisation of reactions that have
evidence for mitochondrial localisation. Extensive curation and manual refinement was used to create a model
called iAS253, containing 253 reactions, 245 metabolites and 89 transport steps across the inner mitochondrial
membrane. To demonstrate the predictive abilities of the model, flux balance analysis was used to calculate
metabolite fluxes under normal conditions and to simulate three metabolic disorders that affect the TCA cycle:
fumarase deficiency, succinate dehydrogenase deficiency and a-ketoglutarate dehydrogenase deficiency.
Conclusion: The results of simulations using the new model corresponded closely with phenotypic data under
normal conditions and provided insight into the complicated and unintuitive phenotypes of the three disorders,
including the effect of interventions that may be of therapeutic benefit, such as low glucose diets or amino acid
supplements. The model offers the ability to investigate other mitochondrial disorders and can provide the
framework for the integration of experimental data in future studies.
Background
Due to the involvement of the mitochondrion in many
essential metabolic processes it is implicated in a wide
and growing variety of disorders and pathologies [1].
However, it is often difficult to elucidate how a disease
phenotype relates to the underlying genetic cause, as
these disorders have complicated and non-intuitive phe-
notypes due to the inherent complexity of mitochondrial
metabolism. A change in a small part of a complex net-
work can affect the overall capabilities of a system, such
as metabolite production, which can be impossible to
predict without a systemic model. Models of metabolism
allow these disorders to be studied by simulating the
effects of a change in enzyme metabolism at a systems
level and modelling these complex phenotypes as the
consequence of changes in metabolic fluxes. Several
models have been created that have attempted to repre-
sent the mitochondrion in its entirety [2-5], although
these reconstructions are far from complete. Their con-
struction has been hindered by the lack of a defined
mitochondrial proteome, as available localisation data is
difficult to query and use in conjunction with metabolic
pathway data. Therefore these models have been limited
to well-established pathways of the mitochondrion.
These models are unlikely to be representative of the
full metabolic capabilities of the mitochondrion, which
may result in difficulties in modelling metabolic disor-
ders that often have complicated and unintuitive pheno-
types caused by complex interactions between reactions
that may not otherwise be obviously interlinked. Evalu-
ating the mitochondrial localization of thousands of
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tions and metabolites is enabled by MitoMiner [6], a
mitochondrial proteomic database that integrates experi-
mental proteomic localization data with annotation
from public resources and metabolic pathway data. The
data and functionality of MitoMiner allows the creation
of a more comprehensive metabolic model and provides
a new opportunity to investigate mitochondrial
metabolism.
Here we describe the construction of a model of mito-
chondrial metabolism in human heart cells called
iAS253 by using the MitoMiner database and other pub-
lic resources. We demonstrate that by using flux balance
analysis (FBA) normal mitochondrial metabolism can be
successfully simulated. The FBA method has been
described in detail elsewhere [7,8], but briefly the main
data required is a stoichiometric matrix (S), which
represents all the reactions and metabolites in the
model. The matrix is used with the assumption that the
model is at a quasi steady state, represented as S ￿ ν =
0, where ν is a flux distribution vector. Capacity and
directionality constraints are then included by defining
u p p e ra n dl o w e rb o u n d s( νmin ≤ ν ≤ νmax) of individual
reactions. Directionality is incorporated by setting either
the upper or lower bound of a reaction to zero.
Although these constraints limit the number of possible
metabolic flux distributions that satisfy the steady state,
a very large number of possible solutions still exist, so a
unique solution representing a flux distribution for the
model is found by using an objective function. The
objective function is a set of criteria chosen to match
the biological objective of the system in vivo and an
optimal flux distribution is found that maximises (or
minimises) this function by using linear programming. If
the objective function of the model matches the biologi-
cal objective of the system, the optimal flux distribution
should correspond with the flux distribution in vivo. For
example a common objective function used for mito-
chondrion metabolism is maximum ATP production, so
to reflect the primary role of the mitochondrion in cel-
lular energy production.
The benefits of the FBA approach are that detailed
kinetic information such as concentrations are not
required, allowing the simulation of large models that
would be infeasible using alternative methods. This
makes the technique particularly attractive in biomedi-
cine, where a phenotype can be the result of many inter-
acting reactions and detailed kinetic information for
each enzyme involved under disease conditions is una-
vailable and difficult to obtain experimentally. Further-
more, the models can be used to discover and assess the
effect of interventions on a disease state that may
restore the system to a normal state and thus be of ther-
apeutic value.
In our new model we account for the most recent
stoichiometric information of the ATP synthase [9],
thermodynamic constraints and reaction directionality,
and the change in protonation state between the mito-
chondrial matrix and the cytosol due to the difference
in pH between these compartments. These are factors
that have not all been accounted for in previous flux
balance analysis simulations of mitochondrial metabo-
lism. Having developed a model that simulates normal
mitochondrial metabolism, we demonstrate the predic-
tive capabilities of our new model, by investigating three
TCA cycle disorders that affect core mitochondrial
metabolism.
The first disorder, fumarase deficiency (OMIM:
606812), is caused by impairment of the fumarate hydra-
tase enzyme, which converts fumarate into malate in the
TCA cycle. The condition is exceptionally rare with
around 40 cases reported globally to date [10]. The
effects of the disorder are acute and include develop-
mental delay, severe mental retardation, language
impairment, seizures and dysmorphic facial features
[10-12]. No medical treatments currently exist and most
patients do not survive past early childhood [12]. In
most of these cases there is almost no residual enzyme
activity [13,14]. The diagnostic markers for this disorder
are the presence of fumarate and 2-oxoglutarate in the
urine, and lactate in the cerebrospinal fluid [13].
The second disorder, succinate dehydrogenase defi-
ciency (OMIM: 252011) affects mitochondrial complex
II, which links the TCA cycle with the electron trans-
port chain by coupling the conversion of succinate to
fumarate to the quinone pool. In cases of isolated succi-
nate dehydrogenase deficiency the phenotype is highly
variable and can include Leigh syndrome [15-17], leuko-
dystrophy [16,17], Kearns-Sayre syndrome [18], cardio-
myopathy [19] and mental and motor skill deterioration
[20]. The onset of symptoms can be from childhood to
adulthood and appears to correlate with residual enzyme
activity, with those with higher complex II activity hav-
ing milder symptoms and diagnosed later in life [21].
The metabolic profile of the disorder is elevated levels
of lactate in blood plasma [16-18,20], and in some cases
oxoglutarate and succinate is present in the urine [22]
and succinate accumulates in brain [15].
The third disorder, a-ketoglutarate dehydrogenase
deficiency (OMIM: 203740) affects the conversion
of oxoglutarate to succinyl-CoA in the TCA cycle. The
condition is extremely rare with only 23 cases recorded
in the literature [23]. Onset of the disorder occurs
shortly after birth and is characterised by encephalopa-
thy and hyperlactatemia resulting in death in early
childhood. The metabolic profile of the disorder is
the excretion of oxoglutarate [24,25] and in many cases
lactate [25,26]. The a-ketoglutarate dehydrogenase
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E3, with the latter subunit also a constituent of the pyr-
uvate dehydrogenase and ketoacid dehydrogenase com-
plexes. Therefore a defect with the E3 subunit can affect
all three enzymes, resulting in a more complicated clini-
cal phenotype.
We show that simulations using our model can repli-
cate the disease state phenotypes of these disorders by
correctly predicting the effects of these perturbations on
normal mitochondrial metabolism. The simulations
show how alternative metabolic pathways can maintain
production of ATP, but lead to the over-production of
other metabolites that must be excreted, as observed in
vivo in the blood, urine and cerebrospinal fluid of
patients. Furthermore, the simulations suggest that
treatments, such as a low glucose diet or amino acid
supplements, may reduce the risk of lactic acidosis and
increase ATP production and thus be of therapeutic
value.
Results
Construction of the mitochondrial metabolic model
The metabolic model of reactions in a human heart
mitochondrion, called iAS253 (designated using a com-
mon naming convention for metabolic networks [27]),
was constructed using the principle of metabolite avail-
ability, where a reaction was only included in the model
if the substrates or products of the reaction were used
elsewhere in the mitochondrial matrix (See Methods for
full details). In total 2187 reactions with evidence of
mitochondrial localisation were evaluated resulting in
the inclusion of 229 reactions that formed a connected
network using 228 metabolites in the mitochondrial
matrix compartment. An additional 24 cytosolic reac-
tions were added to a separate compartment to repre-
sent reactions that were intrinsic to the function of the
mitochondrion, such as glycolysis. 73 boundary condi-
tions were included to represent import and export of
metabolites to the system.
To more accurately reflect the in vivo capabilities of
the mitochondrion and to remove all thermodynamically
disallowed flux loops from the model, 110 of the 258
reactions and 50 of the 89 transport steps in the model
were assigned a directionality constraint. Reaction direc-
tionality was set using thermodynamic information, gen-
eral rules of irreversibility, and information from several
public resources and the primary literature.
The final model contained no orphan metabolites and
all internal flux loops were eliminated. 247 reactions
were capable of having a flux under the current bound-
ary conditions between the cytosol and the matrix, with
the remaining 6 reactions requiring the import of acetal-
dehyde or propanoate to have a flux, which is currently
disallowed in the model. Details of the reactions,
metabolites and constraints included in the model can
be found in Additional Files 1, 2 and 3. The XML
model of iAS253 (Additional File 4) has been deposited
at the EMBL European Bioinformatics Institute’sB i o -
Models database (ID: MODEL1106160000).
Simulation of normal mitochondrial physiology in
cardiomyocytes
Six separate pseudo reactions were devised to denote
the metabolite requirements of the mitochondrion. This
included the production of 20 amino acids required for
protein synthesis, RNA and DNA, haem, ATP and lipids
in a ratio found in the inner mitochondrial membrane
of rat liver mitochondria (phosphatidylcholine 40%,
phosphatidylethanolamine 34%, phosphatidylserine 3%,
cardiolipin 18% [28]). Separate simulations were run set-
ting each of these pseudo reactions as the objective
function (i.e. maximising the flux through the reaction)
and the model was capable of fulfilling all of them. For
example, with simulations using maximum ATP produc-
tion as the objective function, core metabolism worked
correctly with both glucose and lactate converted to pyr-
uvate in the cytosol as appropriate for heart [29], which
was imported into the mitochondrion to take part in the
TCA cycle. NADH was produced by the TCA cycle in
preference to fatty acid and ketone body oxidation
although these processes were still active, and was used
by the reactions representing the electron transport
chain to move protons into the cytosolic compartment.
Reactive oxygen species (ROS) were produced from
complex I at a rate corresponding to 0.1% of the elec-
trons passed through it, as is consistent with recent
experimental findings [30,31]. ATP synthase allowed
these protons to move back into the mitochondrial
matrix compartment, generating ATP in the process.
The maximum ATP production in this simulation was
139.43 μmol/min/gDW, which is similar to the experi-
mentally measured figure of ATP hydrolysis of resting
heart, which is approximately 150 μmol/min/gDW [29].
Both oxygen and glucose uptake were at the maximum
a l l o w a b l er a t e( 1 9 . 8μmol/min/gDW [32] and 0.9 μmol/
min/gDW [33] respectively)a n dt h el a r g e s tf l u x e s
occurred through the protein complexes of the electron
transport chain. When the results of this simulation are
compared to experimentally determined figures, the
TCA cycle had a flux rate of approximately 7.13 μmol/
min/gDW, compared to the experimentally measured
figure of 7.5 μmol/min/gDW in rat [32] while the fatty
acid oxidation rate of 0.41 μmol/min/gDW is similar to
the experimentally determined rate in rat of 0.35 μmol/
min/gDW [34]. Very low levels of alanine, succinate,
and glutamine were effluxed from the system, corre-
sponding with observations of mammalian heart [35-39].
In addition 61% of acetyl-CoA production was derived
Smith and Robinson BMC Systems Biology 2011, 5:102
http://www.biomedcentral.com/1752-0509/5/102
Page 3 of 13from fatty acid degradation, 30% from glycolysis and the
remaining 9% from ketone body degradation, which
compares well with estimates in the literature that 60-
90% of acetyl-CoA production is from fatty acid degra-
dation with the remaining 10-40% from glycolysis [29].
Simulation of mitochondrial disease: 1) Fumarase
deficiency
One of the most noticeable effects of fumarase defi-
ciency is the presence of fumarate in the urine. How-
ever, in the default model there was no mechanism for
the efflux of fumarate from the system. Therefore, to
model fumarase deficiency it was necessary to add an
unconstrained transport step and boundary condition to
allow fumarate in the mitochondrial matrix to leave the
system. Separate simulations were run under each of the
six objective functions with this adapted model and no
flux was observed through the transport step or bound-
ary condition under any simulation under normal condi-
tions, showing that these additions did not affect the
model.
To model fumarase deficiency the reaction that repre-
sents the fumarase enzyme in the model (R01082MM)
was constrained to different flux values representing
reduced enzyme activity and an objective function of
maximum ATP production used. Compared to simula-
tions under normal conditions, the most notable effect
of these constraints was a dramatic drop in maximum
ATP production of up to 96% (Figure 1). Fumarate was
effluxed from the system when the fumarase flux was
constrained to just 97% of its value under normal condi-
tions, while lactate was effluxed at 20% of normal flux
or below. Flux through the fatty acid oxidation pathway
and ketone body degradation became inactive at 28%
and 95% of normal fumarase flux respectively, due to
inability of the acetyl-CoA produced to enter the TCA
cycle, resulting from an inadequate supply of oxaloace-
tate that would normally be derived from fumarate.
To determine if the import of other metabolites could
increase maximum ATP production while fumarase was
impaired, the restrictions on each constrained boundary
condition were removed in separate simulations. This
identified the import of several amino acids, bicarbonate,
and metabolites involved in the malate-aspartate shuttle
as having a substantial effect on ATP production (Figure
2). In the initial simulations of fumarase deficiency,
many of these metabolites were imported at the maxi-
mum rate allowed under normal boundary constraints,
but these uptake rates had a relatively minor effect on
the overall system. Proline, arginine and glutamate were
imported and degraded to enter the TCA cycle as oxo-
glutarate while oxaloacetate, aspartate and malate were
imported via the malate-asparate shuttle to circumvent
the gap in the TCA cycle caused by the fumarase defi-
ciency. Bicarbonate was used for a metabolic bypass to
directly convert pyruvate to oxaloacetate, with the addi-
tion of ATP. The routes of these metabolites into cen-
tral metabolism are shown in Figure 3.
One of the clinical phenotypes of fumarase deficiency
is the presence of oxoglutarate in the urine. In the
model, an efflux of oxoglutarate from the system was
observed when the uptake rates of oxaloacetate, malate,
citrate and isocitrate were increased. The efflux was the
result of the oxoglutarate, and oxodicarboxylate trans-
porters requiring oxoglutarate to be counter exchanged
10 9 8 7 6 5 4 3 2 1 0
0
20
40
60
80
100
120
140
Fumarase flux (µmol/min/gDW) 
M
a
x
i
m
u
m
 
A
T
P
 
p
r
o
d
u
c
t
i
o
n
 
(
µ
m
o
l
/
m
i
n
/
g
D
W
)
Figure 1 Effect of varying fumarase flux on maximum ATP
production. The peak in ATP production at a fumarase flux of
approximately 7 μmol/min/gDW represents the optimum rate
observed under normal conditions.
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Figure 2 Effects of metabolite uptakes on maximum ATP
production while fumarase reaction flux is at 0% of its flux
under normal conditions.
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However, the uptake of citrate and isocitrate had a
small effect on maximum ATP production, increasing it
by only 16% when an artificially large uptake rate of 5
μmol/min/gDW was allowed.
Simulation of mitochondrial disease: 2) Succinate
dehydrogenase deficiency
The results from the simulations of succinate dehydro-
genase deficiency were very similar to that of fumarase
deficiency. The main difference was that when the succi-
nate dehydrogenase reaction (R02164MM) was con-
strained and an objective function of maximum ATP
production used, succinate was effluxed from the system
rather than fumarate. A large drop in ATP production
was also observed that was slightly more pronounced
than fumarase deficiency (Figure S1, Additional File 5),
due to the lack of complex II contributing to the qui-
none pool of the electron transport chain. Fatty acid
oxidation and ketone body degradation became inactive
and lactate was effluxed at very similar levels of residual
enzyme flux to that of fumarase deficiency.
To represent that some patients have some residual
enzyme activity, the import of metabolites that had an
effect on ATP production was investigated at 33% and
0% of flux of normal conditions. Regardless of the flux
level chosen proline, arginine, valine, bicarbonate, aspar-
tate, malate and oxaloacetate were found to have a posi-
tive effect on maximum ATP production (Figures S2
and S3, Additional File 5). The entry routes of these
metabolites into the TCA cycle were the same as under
fumarase deficiency (Figure S4, Additional File 5).
Simulation of mitochondrial disease: 3) a-ketoglutarate
dehydrogenase deficiency
The effect of a-ketoglutarate dehydrogenase deficiency
on maximum ATP production was minor. A reduction
in ATP production of just 5% was observed when flux
through the reaction was constrained to zero and an
objective function of maximum ATP production used.
This was due to the presence of a bypass that converted
oxoglutarate to succinate via succinate semialdehyde
and 4-aminobutanoate (GABA) (R01648MM,
R00261MM and R00713MM). An efflux of oxoglutarate
from the system was observed when the flux through
the bypass was constrained by any level. An efflux of
lactate was not observed under any of these conditions.
To simulate the effect of a defect in the E3 subunit of
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Page 5 of 13a-ketoglutarate dehydrogenase that is shared with pyru-
vate dehydrogenase and ketoacid dehydrogenase enzyme
complexes, the dihydrolipoamide dehydrogenase reac-
tion was also constrained (R07618MM). This resulted in
the production of lactate, as pyruvate from glycolysis
could no longer enter the TCA cycle, but maximum
ATP production remained stable, as fatty acid synthesis
increased proportionally (up 80%, with an enzyme flux
of 0%) to maintain acetyl-CoA production levels.
Discussion
Here we present a new, manually curated metabolic
model of the mitochondrion present in human heart tis-
sue, called iAS253 (Additional File 4). It contains 229
mitochondrial matrix reactions, 24 cytosolic reactions,
89 compartment transport steps and 73 boundary condi-
tions. Each reaction was manually evaluated in conjunc-
tion with the principle of metabolite availability before
incorporation into the model, using 33 mitochondrial
proteomic datasets from the MitoMiner database, com-
bined with annotation from public resources and the lit-
erature. The model includes directionality constraints
based upon general rules of irreversibility, thermody-
namics and information from public resources and the
literature. The resultant model contains no orphan
metabolites and its directionality constraints allow every
reaction in model to potentially possess a flux, while all
flux loops have been eliminated. It is encoded in SBML
format [40], and uses KEGG [41] identifiers where pos-
sible. Therefore, this model should be readily adaptable
for use by other modellers either in isolation or with its
addition to models of cellular metabolism. We believe it
is the most refined model of the mitochondrion cur-
rently available as demonstrated by simulations of nor-
mal conditions, which closely correspond with
experimentally determined flux figures and metabolic
observations of heart. For example, fluxes though the
TCA cycle and fatty acid oxidation pathway while using
the objective function of maximum ATP production
corresponded with measurements in rat heart (7.05 vs.
7.5 and 0.41 vs. 0.35 μmol/min/gDW respectively). The
similarities between the model and the results of experi-
ments in vivo suggest that the modelled flux distribution
of core metabolism is biologically relevant. The minor
discrepancies between the flux figures may be due to
imprecise boundary constraints, the biological objective
in vivo for core metabolism not being described accu-
rately by the model’s objective function of maximum
ATP production, or difficulties in measuring these
values experimentally.
These results are in contrast to those of previous
mitochondrial FBA models [2,3] where a much higher
uptake of oxygen (about 40 nmol/min/gDW) was per-
mitted, while maximum ATP production was 60% lower
when this was set as the objective function. This discre-
pancy may be due to the use of capacity constraints on
the transport steps between the cytosol and mitochon-
drion in these models. These constraints were derived
from uptake rates determined experimentally in vitro,
on isolated carrier proteins in liposomes, so are unlikely
to reflect the uptake rates in vivo for the mitochondrion.
Our model does not use capacity constraints on these
transport steps and instead constrains the system at the
boundary conditions.
The constraints placed on the boundary conditions of
the system critically affected the behaviour of the model.
These constraints reflect the imports and exports of the
system and were chosen carefully from the primary lit-
erature (Additional File 3). There is some uncertainty in
these figures as often the only data available are not
from human and in one case not from heart tissue. In
addition many of these experiments were conducted on
isolated hearts, which may display significant metabolic
differences to hearts in situ [42]. Therefore these figures
may not correspond to the maximum possible uptake
values, which are necessary to set the upper bound of
the constraint. Previous reconstructions have tried to
account for this experimental uncertainty by increasing
these figures by an arbitrary amount, such as 25% [2].
This is problematic because no data exists on what scale
of increase is appropriate whereas the uptake of some
compounds, such as oxygen, are a critical limiting factor
to the system under most circumstances, and will
usually be at the maximum allowable rate. Therefore in
the absence of more relevant data it was decided to use
experimental figures without modification. Further
experiments to determine and verify the uptake rates
used would be beneficial for further refinement of the
model and in particular to aid simulations of perturbed
states where uptakes can have a large impact on model
behaviour. In addition we included directionality con-
straints on the transport steps between the cytosol and
the mitochondrial compartments to prevent flux loops,
while reflecting the biological role of the underlying car-
rier and allowing normal metabolism. However, it is
possible that under disease conditions the accumulation
of metabolites may affect the direction of transport. In
the metabolic disorders investigated here all metabolites
that were experimentally reported as accumulating
could be effluxed without the need to alter these con-
straints. The only exception was fumarate, which is
known to accumulate in fumarase deficiency, where an
extra transport step was included to allow its efflux.
A common objective function used with models of
microorganisms is the production of biomass. Biomass
represents all the metabolites that are required for
growth of that particular organism, with the assumption
that the organism is biologically optimised for maximum
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the biomass are derived from experimental figures mea-
sured from cellular biomass. However, a single biomass
objective function cannot currently be devised for the
mitochondrion, as no experimental figures exist for its
composition. It is also unlikely that the biological objec-
tive in vivo is maximum growth as one of the main
roles of the mitochondrion is to produce ATP and so
this would also have to be incorporated in the objective
function to make it biologically relevant. This would
require the ratios between ATP production and growth
and maintenance of the mitochondrion to be experi-
mentally verified and this is not currently available, and
is likely to be extremely difficult if not impossible to
determine. Therefore to represent the different aspects
of mitochondrial metabolism, six separate pseudo reac-
tions were devised, encompassing growth and mainte-
nance as well as haem and ATP production. Although
maximum ATP production is most likely to be the clo-
sest to the biological objective (as shown with the close
correspondence to experimentally measured figures), the
inclusion of the other pseudo reactions ensures the
model can produce metabolites known to be required
by the mitochondrion. However the flux distributions
found when using these other pseudo reactions indivi-
dually as objective functions are unlikely to be realistic,
as no one objective function in isolation will match the
biological objective of the system in vivo. The pseudo
reactions that are used for these objective functions
have been included in the model for convenience and to
allow other researchers to easily replicate our results.
To demonstrate the predictive abilities of the model
we simulated and analysed the complicated phenotypes
o ft h r e ed i s o r d e r so ft h eT C Ac y c l eu s i n gt h eiAS253
model.
The mechanism of fumarase deficiency
Patients with the most severe symptoms of the disorder
often have residual fumarase activities near zero [22].
This would equate to near zero flux through the fumar-
ase reaction in the model. Under these conditions both
lactate and fumarate were effluxed from the system,
matching the phenotype. Initial simulations would pre-
dict that such a reduction would result in a very large
decrease in maximum ATP production in heart (Figure
1), which would seem likely to have catastrophic effects.
However, heart defects in patients have not been
reported [22], which would imply that the predicted
reduction in ATP production must be compensated. In
a series of simulations the boundary constraints were
removed one by one to determine if increased metabo-
lite uptake could counteract the decrease. This identified
the uptake of valine, aspartate, malate, proline, bicarbo-
nate, oxoaloacetate, arginine, glutamine, serine and
glucose as having a positive effect on ATP production
(Figure 2).
The effect of aspartate on the system supports the
hypothesis of Bourgeron et al. [13], which suggests a
reaction in the malate-aspartate shuttle is used to con-
vert aspartate and oxoglutarate into oxaloacetate and
glutamate, acting as a metabolic bypass and allowing the
impaired part of the TCA cycle to be circumvented.
They suggest the low level of aspartate found in the
blood plasma of two patients in their study supports the
existence of such a bypass. The iAS253 model predicts
that if aspartate is available, this bypass is used. A rela-
tively small uptake resulted in a large difference in max-
imum ATP production, which suggests it could be
biologically relevant.
Oxaloacetate and malate also had a large effect by
using the reactions of the malate-aspartate shuttle. In
the simulations oxaloacetate was converted to malate
before being transported to the matrix using the oxoglu-
tarate transporter. Malate was then converted back into
oxaloacetate to complete the TCA cycle. As a conse-
quence of the transport step oxoglutarate was counter-
exchanged from the matrix into the cytosol and then
effluxed from the system. Such a mechanism in vivo
may explain the oxoglutarate observed in urine of
patients with fumarase deficiency.
The import of proline, arginine, glutamate and valine
caused a large increase in ATP production due to the
degradation of these metabolites into oxoglutarate,
increasing the flux through part of the TCA cycle, and
leading to an increase in fumarate efflux. The model
predicts that a corresponding increase in the efflux of
glutamine and alanine should also be observed. The pro-
duction of glutamine was required to remove the
ammonia produced during the deamination of these
metabolites, whereas alanine efflux was involved in the
glucose-alanine cycle, where pyruvate is converted into
oxoglutarate (Figure 3). However, both of these metabo-
lites are further metabolised in the kidney and liver
respectively, so it is not clear whether they would accu-
mulate to a sufficient degree to be elevated in a patient
metabolite profile.
The uptake of bicarbonate had a large impact on ATP
production by allowing the direct conversion of pyruvate
to oxaloacetate. However, due to the production of lac-
tate, and bicarbonate acting as a cellular buffer, it may
not be available at sufficient levels to have a significant
affect in vivo.
Serine had an effect on increasing ATP production,
but only from its degradation to glycine, producing
NADH and NADPH in the process. It did not directly
contribute to the TCA cycle, which explains why even
at high uptakes its effect on maximum ATP production
is lower than the other metabolites except glucose.
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production the effect was small, while dramatically
increasing lactate efflux. Therefore, although increasing
glucose levels may be easily achieved physiologically, a
low glucose diet, while increasing the levels of the other
metabolites may be more beneficial to maintain ATP
production, while minimising lactic acidosis.
It is not apparent if in vivo the uptakes of any of these
metabolites are increased beyond normal limits and
have a significant impact on ATP production. Although
it may be unlikely that any one metabolite could sustain
a high uptake flux under physiological conditions, it
may be feasible that all of these metabolites contribute
collectively to increasing ATP production. Further
experimental data would be required to test these pre-
dictions and to further refine the model.
A common occurrence throughout these simulations
was fatty acid metabolism was restricted, as acetyl-CoA
could not enter the TCA cycle. If this occurs in vivo,
these excess fatty acids may be stored in adipocytes or
alternatively be expressed as an increase in the produc-
tion of ketone bodies (directionality constraints prevent
this in the current model as only liver produces ketones
while the heart consumes them), a known cellular
method to use excess acetyl-CoA, rather than a reduc-
tion in fatty acid metabolism. This would be supported
by the elevated levels of acetoacetate in the blood
plasma of two patients with the disorder (0.07 and 0.08
mmol/l) in comparison to controls (0.016 - 0.04 mmol/
l), although levels of hydroxybutanoate appeared to be
within the normal range [13]. Additional data from
fumarase deficient patients are needed to verify if these
predictions are correct.
The mechanism of succinate dehydrogenase deficiency
The simulations of succinate dehydrogenase deficiency
were very similar to fumarase deficiency in both the
reduction in ATP production (Figure 1 and Figure S1,
Additional File 5) and the effect of increasing certain
metabolite uptake rates (Figure 2 and Figures S2 and S3,
Additional File 5). The metabolites that had a positive
effect on maximum ATP production were shared
between the two deficiencies and used the same degra-
dation pathways and entry points into the TCA cycle
(Figure 3 and Figure S4, Additional File 5). The main
difference was the efflux of succinate rather than fuma-
rate as found in fumarase deficiency and a slightly lower
level of ATP production, as complex II could no longer
contribute to the electron transport chain. The similari-
ties between the disorders are unsurprising as the
enzymes are adjacent in the TCA cycle. The main phy-
siological difference between them is that many patients
with succinate dehydrogenase deficiency have residual
enzyme activity in the range of 10-50% whereas many
patients with fumarase deficiency have 0% activity [22].
However, it is not possible to predict what level of suc-
cinate dehydrogenase flux this will correspond with, as
residual enzyme activity and enzyme flux are not
directly correlated [43]. However, even low levels of
enzyme flux result in a dramatic increase in maximum
ATP production (Figure S1, Additional File 5). This has
the effect that the uptake rates of metabolites that
impact ATP production can be much lower while
returning production to normal levels (Figure S2, Addi-
tional File 5), which may make these interventions more
physiologically feasible.
The mechanism of a-ketoglutarate dehydrogenase
deficiency
The effect of a-ketoglutarate dehydrogenase deficiency
on maximum ATP production was minor even when no
flux was allowed through the reaction representing the
enzyme. This was the result of a bypass known as the
GABA shunt [44], which converts oxoglutarate to succi-
nate using succinate semialdehyde and GABA as inter-
mediates, circumventing the impaired reaction.
Although the GABA shunt is usually associated with
brain, there is evidence in MitoMiner, and the literature
[44] that it is present in heart. Oxoglutarate was only
effluxed from the system if the flux through the GABA
shunt was limited so that not all the flux could proceed
through it. If the bypass in vivo is unable to sustain the
large flux required for the TCA cycle to function at full
capacity, this could explain the phenotype of oxogluta-
rate excretion. Gene expression data for patients with
the disorder may give some indication whether the
enzymes that constitute the GABA shunt are up-regu-
lated in heart to allow the bypass to function. GABA
also acts as an inhibitory neurotransmitter and its invol-
vement in the bypass may begin to explain the encepha-
lopathy reported in patients.
An efflux of lactate was never observed when only a-
ketoglutarate dehydrogenase was constrained. Therefore
to determine whether a defect in subunit E3 of the
enzyme complex, which is also shared with pyruvate
dehydrogenase and ketoacid dehydrogenase complexes,
was responsible, the reactions representing the latter
were also restricted. Only when pyruvate dehydrogenase
was constrained was lactate produced, as not all pyru-
vate from glycolysis could enter the TCA cycle. This
suggests that a lactic acidosis phenotype is the result of
a defect in the E3 subunit, and isolated a-ketoglutarate
dehydrogenase deficiency can be discounted.
Conclusions
We have successfully simulated metabolism of heart
mitochondria under normal conditions as demonstrated
by close similarity of flux values with experimentally
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ability to simulate the metabolic phenotype of three rare
single gene disorders and illustrate that the model can
provide an insight into the disease mechanism. As the
mitochondrion is involved in many more complicated
disorders including Parkinson’s, diabetes and heart fail-
ure, the next step is to use this model with further
development to simulate and understand these
conditions. We believe that our model can be used as
framework for integrating genomics, proteomics, meta-
bolomics and clinical data and so contribute to the
development of therapies for mitochondrial related
diseases.
Methods
Compartmentalisation and modelling approach
The mitochondrion consists of four distinct compo-
nents: the outer mitochondrial membrane, the inter-
membrane space, the inner mitochondrial membrane,
and the mitochondrial matrix. For modelling metabo-
lites, no distinction is required between the intermem-
brane space, outer mitochondrial membrane and the
cytosol, as porins in the outer mitochondrial membrane
allow any molecule below 3-6 kDa to exchange freely
between the cytosol and the intermembrane space. In
contrast the inner mitochondrial membrane is imperme-
able to most metabolites [45] and the exchange of meta-
bolites between the mitochondrial matrix and the
cytosol requires a transporter in the inner mitochondrial
membrane [46]. Therefore, the model has two compart-
ments, one to represent the cytosolic side of the inter-
membrane space and another for the mitochondrial
matrix, with the model focused on metabolic reactions
in the latter compartment. Reaction localisation was
determined using the principle of metabolite availability,
where a reaction can only be present if its substrates are
available and its products can be used within the same
compartment.
Metabolite availability from mitochondrial transporters
Initial metabolite availability within the mitochondrial
matrix was determined with the addition of inner mito-
chondrial membrane transporters to the model and
defining the metabolite requirements of the mitochon-
drion. The inner mitochondrial membrane transporters
represent the members of the mitochondrial transporter
family, many of which are characterised and their sub-
strates and transport mechanism (i.e. uniport, antiport,
symport, proton coupled) are known [46,47]. Some car-
riers can transport many related metabolites, so each
possible combination was separately included into the
model with the appropriate transport mechanism. Each
transport step was modelled as a reaction where only
the subcellular localisation of the metabolites changed.
Addition of known mitochondrial matrix reactions
The next step in defining metabolite availability was the
addition of reactions known to take place in the mito-
chondrial matrix (Additional File 1). From the MitoMi-
ner database all proteins with an Enzyme Commission
(EC) number that had annotation in either UniProt [48]
or the Gene Ontology [49] as localising to the mito-
chondrial matrix were identified. MitoMiner was used
to find the corresponding reactions in KEGG for each
EC number. Every reaction was manually inspected to
uncover any erroneous annotation by cross-referencing
with the experimental data from MitoMiner, BRENDA
[50] and the primary literature to confirm the protein
was present in human, expressed in heart tissue and
localised to the mitochondrial matrix. If the reaction
met these criteria it was added to the model. This pro-
cess was repeated for proteins annotated as localising to
the inner mitochondrial membrane. The identified reac-
tions were assigned to a compartment based on which
side of the inner mitochondrial membrane the protein
has its active site. If this information was unavailable it
was evaluated under the criteria used in model exten-
sion section, below. To ensure that all known mitochon-
drial matrix reactions were included, the reactions of
established mitochondrial processes, such as amino acid
degradation, were obtained from KEGG and included if
absent.
Model extension via metabolite availability
The model was extended by identifying orphan metabo-
lites that were used in only one reaction and searching
for further reactions that could produce or consume
them. Each new reaction was evaluated for localisation
using information from MitoMiner, UniProt, the Gene
Ontology, BRENDA and the primary literature. If the
evidence and annotation for mitochondrial localisation
was convincing (Additional File 1), or if the reaction
was spontaneous, it was added to the model. If this
addition created a new orphan metabolite, the process
was repeated with the new metabolite. As reactions that
use orphan metabolites are unable to have a flux and so
do not contribute to the model, if a suitable reaction
could not be found to produce or consume an orphan
metabolite in the mitochondrial matrix, the metabolite
was considered to be unavailable and the reaction that
generated it was removed from the model. In excep-
tional cases where an orphan metabolite had strong evi-
d e n c et h a ti tw a sp r e s e n tw i t h i nt h em i t o c h o n d r i a l
matrix but used or produced outside it, such as pyru-
vate, or was required to fulfil an objective function, such
as an amino acid, then a transport step was added to
the model. Once all the orphan metabolites had been
resolved, all remaining reactions that had evidence or
annotation in MitoMiner for mitochondrial localisation
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added to the model where appropriate.
Cytosolic reactions and boundary conditions
Although the model was focused on the mitochondrial
matrix, some cytosolic reactions were incorporated.
These included reactions representing the cytosolic side
of the malate-aspartate, glycerol-phosphate and carnitine
shuttles as well as the cytosolic steps required for haem
synthesis. As pyruvate uptake rates into the mitochon-
drion are unavailable, but the cellular uptake of glucose
has been measured experimentally, the reactions of gly-
colysis were also included. Finally, boundary conditions
constrained to experimentally derived figures from the
primary literature (Additional File 3) were added to the
model to reflect the import and export of metabolites
into the system from the cytosol of both common meta-
bolites and the metabolite orphans present in the cyto-
sol compartment. In some cases the only information
available was from non-human species or non-heart tis-
sue types.
Reaction protonation
All the reactions included were protonated at the pH of
either the matrix or the cytosol. The pH of the mito-
chondrial matrix differs markedly from that of the cyto-
sol resulting in a difference of protonation state for
some metabolites, particularly those containing phos-
phate groups. The protonation state is particularly rele-
vant for a mitochondrial model as changes in free
protons can affect the electron transport chain and,
therefore, the maximum ATP objective function. As all
reactions in KEGG are at neutral pH, the reactions in
the model were protonated according to the major
microspecies found at a pH of 8.05 for the mitochon-
drial matrix [51] and 7.3 for the cytosol. These calcula-
tions were performed using the Marvin suite of
computational chemistry software (ChemAxon Ltd,
Budapest, Hungary). Any ambiguous ‘R’ chemical groups
present in the compounds were ignored for the pur-
poses of these calculations. The stoichiometry of the
protonated reactions used in the model can be found in
the supplementary information. In addition, the stoi-
chiometry of ATP synthase was altered to reflect the lat-
est structural and biochemical information [9].
Objective functions
Six pseudo reactions were defined to represent the
metabolite requirements of essential mitochondrial pro-
cesses: the availability of 20 amino acids for protein
synthesis, nucleotides for DNA and RNA synthesis,
lipids in the ratio present in the inner mitochondrial
membrane for lipid synthesis and the production of
ATP and haem. These pseudo reactions were included
in the model and used individually as the objective func-
tions in simulations. For example maximising the pro-
duction of ATP.
Model format and in silico analysis
The model was encoded in SBML format and validated
using the SBML validator tool [52]. KEGG identifiers
were used where possible for the identifiers of reactions
and metabolites so they could be easily identified and to
fulfil MIRIAM [53] requirements. To denote the com-
partment of each reaction and metabolite the following
were appended to the KEGG identifier: ‘MM’ for mito-
chondrial matrix, ‘Cyto’ for cytosolic and ‘_b’ for bound-
ary. The metabolic capabilities of the model were
calculated using flux balance analysis. The six defined
objective functions were used in flux balance analysis to
find unique flux distributions of the model under differ-
ent conditions. All simulations were carried out in
MATLAB (MathWorks, Inc., Natick, MA) using the
COBRA toolbox [54] and the linear programming solver
GLPK (http://www.gnu.org/software/glpk). Networks
were visualised using Cytoscape [55]. All graphs were
generated using the COBRA toolbox. All reported flux
values are μmol/min/gram of dry weight (DW).
Reaction reversibility and directionality constraints
Reversibility of all the reactions was manually evaluated
and a direction assigned using general rules of irreversi-
bility [56] and estimates of ΔG determined using the
group contribution method [57]. If none of these criteria
were applicable the reaction was considered to be rever-
sible. Details of each assignment can be found in Addi-
tional File 1.
Additional constraints on the directionality of the
reactions and transporters in the model were applied to
prevent thermodynamically disallowed flux loops occur-
ring, known as type II and III extreme pathways [58].
Internal flux loops were identified by running a simula-
tion under each objective function while all boundary
conditions were constrained to zero, preventing any
influx or efflux of metabolites to the system. Under
these conditions all fluxes in the system should be zero
with any observed fluxes the result of loops. Loops were
eliminated with the addition of directionality informa-
tion from the primary literature, KEGG, BRENDA and
HumanCyc [59]. Where necessary, transport steps in the
model were also constrained to one direction to prevent
loops. These were particularly prevalent as many of the
transport steps use a similar set of metabolites as they
represent different metabolite combinations that are
capable of being transported by the same mitochondrial
carrier. As thermodynamics and rules of directionality
c a n n o tb ea p p l i e db e c a u s et h ef r e ee n e r g yc h a n g eo f
exchange is zero under standard conditions, they were
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For example as the function of the oxoglutarate carrier
is to exchange cytosolic malate for oxoglutarate in the
matrix as part of the malate-asparate shuttle [46], this
directionality can be applied to the transport step. Addi-
tional simulations were conducted to ensure each reac-
tion in the model was still capable of having a flux with
these directionality constraints, with alterations where
necessary, while still eliminating loops.
To prevent unrealistic flux distributions from the
unlimited uptake or efflux of metabolites, the fluxes
through the boundary conditions were constrained. To
determine which boundary conditions had a critical
effect on the model and so required constraining, all
boundary conditions were set to an arbitrarily small
upper bound value of 0.01 μmol/min/gDW. Each
boundary condition was unconstrained one by one and
simulations were run for each objective function. Any
large influx or efflux from an unconstrained boundary
condition was investigated and constrained to experi-
mentally determined values obtained from the primary
literature with conversions to the correct units (μmol/
min/gDW) where appropriate. A wet to dry weight con-
version of five times was used where required, based
upon the study of isolated mouse hearts [60]. In some
cases experimental figures were unavailable but direc-
tionality could be assigned to the boundary condition to
prevent an unrealistic flux. Finally a simulation under
each objective function was carried out to determine
whether the fluxes representing core metabolism
reflected that found in vivo. If core metabolism was dis-
rupted by the import of a metabolite, the unconstrained
boundary condition was identified and constrained to an
experimentally determined value or directionality.
Modelling of disease
Fumarase deficiency was modelled by constraining the
fumarase reaction (R01082MM) to various percentages
of its flux under normal conditions. Due to the non-lin-
earity between enzyme activity and reaction flux in net-
works [43], it is not possible to associate these
percentages with residual fumarase activities from
patients with the disease [13,14,52,61]. One of the major
phenotypes of the disorder is the presence of fumarate
in the urine. However, there is no mechanism in the
default model for its efflux. Therefore a transport step
and boundary condition were added to the model to
allow the efflux of fumarate produced in the matrix. No
other alterations were made to the default model. To
determine the effect of these constraints on fumarase, a
simulation was run using each of the six objective func-
tions described previously. Separate simulations were
run to determine the effect of un-constraining each
boundary condition on the system.
To model succinate dehydrogenase deficiency the
reaction that represents the enzyme (R02164MM) was
constrained to a maximum of 33% and then 0% of its
flux when the objective function was set to maximum
ATP production. The 33% figure was chosen to repre-
sent that there is some residual enzyme activity in many
patients, but as this does not directly correlate with flux,
an arbitrary reduction in flux was chosen. No other
alterations to the model were made. Simulations were
carried out using each of the six objective functions.
The effect of un-constraining each boundary condition
on the system was then determined in separate
simulations.
The disorder of a-ketoglutarate dehydrogenase defi-
ciency was modelled by constraining the reaction flux of
the initial oxidation reaction of 2-oxoglutarate
(R01700MM) to 33% of its level under normal conditions
to represent reduced enzyme activity. Separate simula-
tions was performed where the reaction shared with pyr-
uvate dehydrogenase and ketoacid dehydrogenase
complexes (R07618MM) were also constrained to various
levels of the normal reaction flux to simulate the effects
of a defect in the E3 subunit, which are shared between
the complexes. In both cases simulations were carried
out using each of the six objective functions.
Additional material
Additional file 1: Reaction details. Excel file detailing the reactions
included in the model including the applied directionality, evidence for
mitochondrial localisation and corresponding KEGG identifier, where
applicable.
Additional file 2: Metabolite details. Excel file detailing the metabolites
included in the model, the assigned compartment and corresponding
KEGG identifier.
Additional file 3: Applied constraints. Excel file detailing the
constraints placed on the boundary conditions and the mitochondrial
transport steps.
Additional file 4: iAS253 metabolic model in SBML format. XML file
of the iAS253 model, in SBML format. Boundary constraints and biomass
pseudo reactions are included.
Additional file 5: Supplementary Figures. Supplementary Figure S1.
Graph of the effect of varying succinate dehydrogenase flux on
maximum ATP production. Supplementary Figure S2. Effects of
metabolites on maximum ATP production while succinate
dehydrogenase deficiency flux is at 33% of its flux under normal
conditions. Supplementary Figure S3. Effects of metabolites on
maximum ATP production while succinate dehydrogenase deficiency flux
is at 0% of its flux under normal conditions. Supplementary Figure S4.
The active pathways (red) that contribute to ATP production during
succinate dehydrogenase deficiency. Black dotted lines show pathways
that are inactive.
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